Recall of Device Recall ProteusPLUS

According to U.S. Food and Drug Administration, this recall involved a device in United States that was produced by Ion Beam Applications S.A..

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
    Recall
  • Event ID
    76696
  • Event Risk Class
    Class 2
  • Event Number
    Z-1695-2017
  • Event Initiated Date
    2017-03-09
  • Event Date Posted
    2017-03-23
  • Event Status
    Open, Classified
  • Event Country
  • Event Source
    USFDA
  • Event Source URL
  • Notes / Alerts
    U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
    The Parent Company was added by ICIJ.
    The parent company information is based on 2017 public records.
  • Extra notes in the data
    System, radiation therapy, charged-particle, medical - Product Code LHN
  • Reason
    The proton therapy system can allow gantry rotation even if the snout is not properly locked.
  • Action
    A Field Safety Notice was mailed or handed to affected customers to inform them of the issue. The notice provides information on the issue, the risk for the patient and user and actions to be taken before starting gantry rotation. Corrective action developed by IBA are detailed.

Device

  • Model / Serial
    Serial numbers: PAT.000, PAT.001, PAT.003, PAT.006, PAT.108, PAT.111, SAT.119, SAT.120
  • Product Classification
  • Device Class
    2
  • Implanted device?
    No
  • Distribution
    Distributed in MA, FL, VA, and TN. China, South Korea, France and Germany
  • Product Description
    Proteus 235
  • Manufacturer

Manufacturer

  • Manufacturer Address
    Ion Beam Applications S.A., Chemin du Cyclotron, 3, Louvain La Neuve Belgium
  • Manufacturer Parent Company (2017)
  • Source
    USFDA